74 results
Page 2 of 4
8-K
EX-99.1
0ihsfzl u60p7lzt
15 Mar 22
Windtree Completes Enrollment of Phase 2 Study of Istaroxime in Early Cardiogenic Shock
7:04am
8-K
EX-99.1
akf5cl5k3qqsn1tp
10 Nov 21
Windtree Therapeutics Reports Third Quarter 2021 Financial Results and Provides Key Business Updates
4:05pm
8-K
EX-99.1
2h15m76i7 mjpfj
5 Aug 21
Windtree Therapeutics Reports Second Quarter 2021 Financial Results and Provides Key Business Updates
5:31pm
8-K
EX-99.1
6jp tnxn67nyb6aa7fo
13 May 21
Windtree Therapeutics Reports First Quarter 2021 Financial Results and Provides Key Business Updates
7:34am
8-K
EX-99.1
1bbo1dv4wmh bgd5jh
29 Mar 21
Windtree Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results and Provides Key Business Updates
5:26pm
8-K
EX-99.1
3x1rovsip00xv
16 Nov 20
Windtree Therapeutics Reports Third Quarter 2020
7:40am
8-K
EX-99.1
94f2dd63k4 c7
1 Oct 20
Windtree Announces First Patient Dosed in Phase 2 Study of Istaroxime for the Acute Treatment of Early Cardiogenic Shock in Heart Failure Patients
7:36am
8-K
EX-99.1
i1ejfdnk6fw8s22
29 Sep 20
Other Events
7:37am
8-K
EX-99.1
kgzypqitj87nk dux
14 Aug 20
Windtree Therapeutics Reports Second Quarter 2020 Financial Results and Provides Key Business Updates
6:07am
8-K
EX-99.1
2g6g y110z4lo5u6
22 May 20
Windtree Therapeutics Announces Pricing of $20.0 Million Public Offering and Uplisting to the Nasdaq Capital Market
5:22pm
8-K
EX-99.2
dkr yzflxur9aoawwv5l
22 May 20
Windtree Therapeutics Announces Pricing of $20.0 Million Public Offering and Uplisting to the Nasdaq Capital Market
5:22pm
424B4
sjtujgm s0
21 May 20
Prospectus supplement with pricing info
6:04am
8-K
EX-99.1
3md8n
14 May 20
Windtree Therapeutics Reports First Quarter 2020 Financial Results and Provides Key Business Updates
8:12am
S-1/A
e4gghxl2j9
6 May 20
IPO registration (amended)
5:31pm